RxDoctor Payments Data

Rebecca Rosado, MD

Foot & Ankle Surgery · El Paso, TXNPI 1063609873

Payments from drug & device makers

$7,200in general payments, 2019–2025

Across 81 payments — averaging $88.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • DJO, LLC$4K
  • Stryker$2K
  • Smith+Nephew$619
  • Treace Medical Concepts, Inc.$212
  • Averitas Pharma Inc.$131
  • Terumo Medical Corporation$64
  • plus $245 from 11 others

What the payments were for

  • Travel & lodging$96913%
  • Food & beverage$2,33332%
  • Other$3,89754%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,200 in reported general payments places this provider in the 65th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas

Medicare billing

Part B allowed, 2024
$69,753
Medicare patients
153
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clobetasol EmollientClobetasol Propionate/Emoll97$54,238
Desonide70$30,941
Diclofenac Sodium15$13,384
SantylCollagenase Clostridium Hist.19$12,739
Clobetasol Propionate44$10,351
Mometasone Furoate58$4,934
Naftifine Hcl13$3,628
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc12$1,629
Betamethasone Valerate11$1,295
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav74$883
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen41$545
Naproxen66$498
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip18$430
Tramadol Hcl51$248
Ibuprofen16$234

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$619$12,73919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 684 foot & ankle surgery providers in Texas.

Other foot & ankle surgery in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →